free counter
World

Bayer initiates asundexian Phase III study program

The logo of Bayer AG is pictured on the facade of the historical headquarters of the German pharmaceutical and chemical maker in Leverkusen, Germany, April 27, 2020. REUTERS/Wolfgang Rattay/File Photo

Register now for FREE unlimited access to Reuters.com

BERLIN, Aug 28 (Reuters) – Germany’s Bayer (BAYGn.DE) said on Sunday it was starting a Phase III study program to investigate the efficacy and safety of asundexian, an oral Factor XIa (FXIa) inhibitor.

The drug candidate is a potential new treatment for patients with atrial fibrillation and in patients with a non-cardioembolic ischemic stroke or high-risk transient ischemic attack, Bayer said.

Bayer’s best-selling stroke prevention pill Xarelto, in which partner Johnson & Johnson (JNJ.N) holds some rights, will lose patent protection around 2026. read more

Register now for FREE unlimited access to Reuters.com

Writing by Paul Carrel, Editing by Miranda Murray

Our Standards: The Thomson Reuters Trust Principles.

Read More

Related Articles

Leave a Reply

Your email address will not be published.

Back to top button

Adblock Detected

Please consider supporting us by disabling your ad blocker